Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Vivos Therapeutics, Empower Sleep launch new cooperative relationship » 07:38
08/26/21
08/26
07:38
08/26/21
07:38
VVOS

Vivos Therapeutics

$5.12 /

-0.32 (-5.88%)

Vivos Therapeutics…

Vivos Therapeutics announced a new cooperative relationship with Empower Sleep, a company providing accessible and personalized telemedicine sleep care, to provide critical diagnostic and medical consultation services to people across North America who suffer from obstructive sleep apnea, OSA. "Vivos and Empower Sleep plan to leverage each company's core technologies to provide a user-friendly platform with personalized insights for patients who are being screened for OSA by North American dentists and other healthcare providers," the company said. Central to this collaboration is the Company's VivoScore product, powered by SleepImage, a biometric ring recording device that allows patients to readily take a sleep test in their own homes. The test results will be automatically uploaded and interpreted by independent physicians and personnel at Empower Sleep. From there, treatment or a telemedicine consultation may be recommended, or a consult with a medical doctor and dentist may be scheduled. "Our trained providers' VivoScore sleep test use has increased by more than 300 percent from just a few weeks ago," said Kirk Huntsman, Vivos Chairman and CEO. "What's more, about half of those patients are testing positive for OSA. Simply put, VivoScore is gaining traction, and we believe that this new cooperative relationship with Empower Sleep will add a vital medical diagnostic and consultative component to our patient-friendly sleep apnea treatment ecosystem. We believe that more screenings and confirmed diagnoses of OSA mean that more patients will seek what is often lifesaving treatment for their OSA, which may include using the Vivos System."

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$5.12 /

-0.32 (-5.88%)

VVOS Vivos Therapeutics
$5.12 /

-0.32 (-5.88%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
VVOS Vivos Therapeutics
$5.12 /

-0.32 (-5.88%)

  • 11
    Dec
VVOS Vivos Therapeutics
$5.12 /

-0.32 (-5.88%)

Hot Stocks
Vivos Therapeutics says FDA denies 510(k) application for DNA appliance » 07:34
08/23/21
08/23
07:34
08/23/21
07:34
VVOS

Vivos Therapeutics

$3.82 /

+0.31 (+8.83%)

The FDA has denied…

The FDA has denied Vivos' previously submitted, additional 510(k) application for its DNA appliance. The DNA appliance is already registered with the FDA as a Class I device for palatal expansion and is currently being used by Vivos-trained clinicians accordingly. Vivos expects to appeal the FDA's decision or resubmit the 510(k) application to the FDA in the coming weeks. This denial does not impact the existing use of the DNA appliance by licensed, trained dentists, and the Company does not believe that this development will have a near- or long-term impact on its operational results or future prospects.

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

  • 11
    Dec
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

Hot Stocks
Vivos Therapeutics receives 510(k) market clearance for mmRNA device » 07:33
08/23/21
08/23
07:33
08/23/21
07:33
VVOS

Vivos Therapeutics

$3.82 /

+0.31 (+8.83%)

Vivos Therapeutics…

Vivos Therapeutics announced the U.S. Food and Drug Administration has granted 510(k) market clearance to Vivos' mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults. This FDA clearance paves the way for expanded insurance reimbursement coverage for the mmRNA device, including Medicare, as well as for potential future government contracts and reimbursement from commercial payers that follow Medicare guidelines.

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

  • 11
    Dec
VVOS Vivos Therapeutics
$3.82 /

+0.31 (+8.83%)

Over a month ago
Conference/Events
Investor Summit Group to hold a virtual summit » 09:27
08/18/21
08/18
09:27
08/18/21
09:27
ZEN

Zendesk

$120.87 /

+0.685 (+0.57%)

, VVOS

Vivos Therapeutics

$3.37 /

+0.53 (+18.66%)

, MEEC

Midwest Energy Emissions

/

+

, PYPD

PolyPid

$7.90 /

-0.3 (-3.66%)

, ANPC

AnPac Bio

$3.66 /

-0.16 (-4.19%)

, FGF

FG Financial

$4.77 /

-0.13 (-2.65%)

, VRAR

Glimpse Group

$8.02 /

-0.33 (-3.95%)

, SAFE

Safehold

$89.00 /

+0.74 (+0.84%)

, ARTL

Artelo Biosciences

/

+

, ARC

ARC Document

$2.67 /

-0.12 (-4.30%)

, GET

Gaylord Entertainment

/

+

, VLON

Vallon Pharmaceuticals

$4.02 /

+0.1 (+2.55%)

, HCDI

Harbor Custom Development

$2.95 /

-0.1 (-3.28%)

, KULR

KULR Technology

$2.04 /

-0.16 (-7.27%)

, SPI

SPI Energy

$4.81 /

-0.155 (-3.13%)

, ABIO

ARCA Biopharma

$2.88 /

+0.11 (+3.97%)

, BTN

Ballantyne Strong

$3.42 /

-0.03 (-0.87%)

, DTSS

Datasea

$1.84 /

-0.125 (-6.38%)

, RESN

Resonant

$2.67 /

-0.09 (-3.27%)

Q3 Virtual Investor…

Q3 Virtual Investor Summit to be held on August 17-18. Webcast Link

ShowHide Related Items >><<
ZEN Zendesk
$120.87 /

+0.685 (+0.57%)

VVOS Vivos Therapeutics
$3.37 /

+0.53 (+18.66%)

VRAR Glimpse Group
$8.02 /

-0.33 (-3.95%)

VLON Vallon Pharmaceuticals
$4.02 /

+0.1 (+2.55%)

SPI SPI Energy
$4.81 /

-0.155 (-3.13%)

SAFE Safehold
$89.00 /

+0.74 (+0.84%)

RESN Resonant
$2.67 /

-0.09 (-3.27%)

PYPD PolyPid
$7.90 /

-0.3 (-3.66%)

MEEC Midwest Energy Emissions
/

+

KULR KULR Technology
$2.04 /

-0.16 (-7.27%)

HCDI Harbor Custom Development
$2.95 /

-0.1 (-3.28%)

FGF FG Financial
$4.77 /

-0.13 (-2.65%)

DTSS Datasea
$1.84 /

-0.125 (-6.38%)

BTN Ballantyne Strong
$3.42 /

-0.03 (-0.87%)

ARTL Artelo Biosciences
/

+

ANPC AnPac Bio
$3.66 /

-0.16 (-4.19%)

ABIO ARCA Biopharma
$2.88 /

+0.11 (+3.97%)

ZEN Zendesk
$120.87 /

+0.685 (+0.57%)

05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 UBS
Zendesk upgraded to Buy from Neutral at UBS
04/30/21 Piper Sandler
Zendesk price target raised to $186 from $180 at Piper Sandler
04/22/21 Wolfe Research
Zendesk initiated with an Outperform at Wolfe Research
VVOS Vivos Therapeutics
$3.37 /

+0.53 (+18.66%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
MEEC Midwest Energy Emissions
/

+

PYPD PolyPid
$7.90 /

-0.3 (-3.66%)

07/30/21
Fly Intel: Top five analyst initiations
07/30/21 Cantor Fitzgerald
PolyPid initiated with an Overweight at Cantor Fitzgerald
07/30/21 Cantor Fitzgerald
PolyPid initiated with an Overweight at Cantor Fitzgerald
11/24/20 Raymond James
Raymond James upgrades PolyPid to Strong Buy after BTD for D-PLEX
ANPC AnPac Bio
$3.66 /

-0.16 (-4.19%)

FGF FG Financial
$4.77 /

-0.13 (-2.65%)

VRAR Glimpse Group
$8.02 /

-0.33 (-3.95%)

SAFE Safehold
$89.00 /

+0.74 (+0.84%)

07/30/21 Truist
Safehold price target raised to $80 from $72 at Truist
07/27/21 B. Riley
Safehold price target raised to $110 from $100 at B. Riley
07/22/21 Truist
Truist 'not overly concerned' by Safehold earnings miss
06/23/21
Fly Intel: Top five analyst initiations
ARTL Artelo Biosciences
/

+

02/12/21 Ladenburg
Artelo Biosciences initiated with a Buy at Ladenburg
01/07/21 Maxim
Artelo Biosciences upgraded to Buy from Hold at Maxim
01/07/21 Maxim
Artelo Biosciences upgraded to Buy from Hold at Maxim
ARC ARC Document
$2.67 /

-0.12 (-4.30%)

GET Gaylord Entertainment
/

+

VLON Vallon Pharmaceuticals
$4.02 /

+0.1 (+2.55%)

HCDI Harbor Custom Development
$2.95 /

-0.1 (-3.28%)

KULR KULR Technology
$2.04 /

-0.16 (-7.27%)

SPI SPI Energy
$4.81 /

-0.155 (-3.13%)

ABIO ARCA Biopharma
$2.88 /

+0.11 (+3.97%)

BTN Ballantyne Strong
$3.42 /

-0.03 (-0.87%)

DTSS Datasea
$1.84 /

-0.125 (-6.38%)

RESN Resonant
$2.67 /

-0.09 (-3.27%)

07/27/21 Benchmark
Benchmark starts Resonant at Buy with $6 price target
07/27/21 Benchmark
Resonant initiated with a Buy at Benchmark
ZEN Zendesk
$120.87 /

+0.685 (+0.57%)

VVOS Vivos Therapeutics
$3.37 /

+0.53 (+18.66%)

VRAR Glimpse Group
$8.02 /

-0.33 (-3.95%)

VLON Vallon Pharmaceuticals
$4.02 /

+0.1 (+2.55%)

SAFE Safehold
$89.00 /

+0.74 (+0.84%)

RESN Resonant
$2.67 /

-0.09 (-3.27%)

PYPD PolyPid
$7.90 /

-0.3 (-3.66%)

MEEC Midwest Energy Emissions
/

+

KULR KULR Technology
$2.04 /

-0.16 (-7.27%)

HCDI Harbor Custom Development
$2.95 /

-0.1 (-3.28%)

ARTL Artelo Biosciences
/

+

ANPC AnPac Bio
$3.66 /

-0.16 (-4.19%)

  • 04
    Feb
  • 10
    Feb
  • 13
    Jan
  • 11
    Dec
  • 11
    Nov
  • 09
    Oct
  • 01
    Oct
ZEN Zendesk
$120.87 /

+0.685 (+0.57%)

VRAR Glimpse Group
$8.02 /

-0.33 (-3.95%)

SPI SPI Energy
$4.81 /

-0.155 (-3.13%)

SAFE Safehold
$89.00 /

+0.74 (+0.84%)

KULR KULR Technology
$2.04 /

-0.16 (-7.27%)

HCDI Harbor Custom Development
$2.95 /

-0.1 (-3.28%)

VVOS Vivos Therapeutics
$3.37 /

+0.53 (+18.66%)

SPI SPI Energy
$4.81 /

-0.155 (-3.13%)

PYPD PolyPid
$7.90 /

-0.3 (-3.66%)

ANPC AnPac Bio
$3.66 /

-0.16 (-4.19%)

Hot Stocks
Vivos Therapeutics reports details of obstructive sleep Apnea study » 16:13
08/17/21
08/17
16:13
08/17/21
16:13
VVOS

Vivos Therapeutics

$3.45 /

+0.61 (+21.48%)

Vivos Therapeutics …

Vivos Therapeutics announced a more detailed summary of the national study results announced by the Company on July 13. As previously announced, one in four patients in the study treated with Vivos' FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, which is defined as patients having an Apnea Hypopnea Index score of less than five post-treatment. The more detailed study data now available reports that prior to treatment, 20 patients had severe OSA, which, from an AHI perspective, improved or is improving by 53%. Of these 20 patients, none have reported worsening of their OSA symptoms, while 3 patients still have severe OSA, 12 have moderate OSA, 4 have mild OSA and 1 has no OSA. The study data also reports that for the 18 patients who began the study with moderate OSA, the average percent improvement in AHI score is 64%. One patient's AHI score worsened by 1 category , while another slightly increased by 2.1. The balance of the patients had improved AHI scores by an average of 64%. After treatment or mid-treatment, 2 patients remained moderate, 10 have mild symptoms and 5 have resolved their OSA symptoms. In addition, 36 patients in the study had mild symptoms pre-treatment. Of these, 1 now has severe symptoms, 4 have moderate symptoms, 16 have mild symptoms and 15 have no symptoms of OSA. Commenting on the additional study data, Kirk Huntsman, Vivos' Chairman and CEO, stated, "By addressing maxillary palatal deficiencies, we believe Vivos' treatment protocols represent an improvement over CPAP and mandibular advancement devices with 27% of the study participants reporting a complete resolution of their OSA symptoms. These measurements are taken without a Vivos appliance in the mouth, whereas MAD measurements are taken with the appliance in place. The more detailed data now available from this study confirms that the Vivos device works well for many patients, with the study showing very strong and statistically significant evidence for an increase in airway volume and transpalatal width. We know the investment community and other interested parties have been looking for more real world data about our devices, so we are pleased to share this more detailed study summary and its positive results."

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$3.45 /

+0.61 (+21.48%)

VVOS Vivos Therapeutics
$3.45 /

+0.61 (+21.48%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
VVOS Vivos Therapeutics
$3.45 /

+0.61 (+21.48%)

  • 11
    Dec
VVOS Vivos Therapeutics
$3.45 /

+0.61 (+21.48%)

Earnings
Vivos Therapeutics reports Q2 EPS (19c), two est. (18c) » 16:19
08/12/21
08/12
16:19
08/12/21
16:19
VVOS

Vivos Therapeutics

$2.70 /

-0.07 (-2.53%)

Reports Q2 revenue $4.5M,…

Reports Q2 revenue $4.5M, two est. $3.6M. Gross margin was 81% for the second quarter of 2021, compared to 83% for the second quarter of 2020, and remained consistent at 79% for the first six months of both 2021 and 2020, reflecting high margin service revenues.

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$2.70 /

-0.07 (-2.53%)

VVOS Vivos Therapeutics
$2.70 /

-0.07 (-2.53%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
  • 11
    Dec
VVOS Vivos Therapeutics
$2.70 /

-0.07 (-2.53%)

Hot Stocks
Vivos Therapeutics opens international training center in Denver » 08:22
07/29/21
07/29
08:22
07/29/21
08:22
VVOS

Vivos Therapeutics

$3.13 /

-0.47 (-13.06%)

Vivos Therapeutics…

Vivos Therapeutics announced that the company has opened The Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from around the world in a live and hands-on setting. "Part of our mission is to spread the word about OSA among healthcare professionals who can help treat it. This new facility can accommodate 300 to 400 healthcare professionals a day, which not only significantly increases our clinical training capacity but also enables us to leverage the technology that we've built into the center to provide the highest-quality training for dentists all over the country and the world," said Kirk Huntsman, Vivos Chairman and CEO. "The Institute's opening (which augments the online training we established over the last year and half) represents a critical milestone for us as we train independent dentists whose patients suffer from dentofacial malformations that may be associated with OSA and other debilitating health conditions. We are also proud that we are able to open our Vivos Institute as promised with the proceeds of our initial public offering that occurred just eight months ago."

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$3.13 /

-0.47 (-13.06%)

VVOS Vivos Therapeutics
$3.13 /

-0.47 (-13.06%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
  • 11
    Dec
VVOS Vivos Therapeutics
$3.13 /

-0.47 (-13.06%)

Hot Stocks
Vivos Therapeutics announces results from national study on airway function » 08:16
07/13/21
07/13
08:16
07/13/21
08:16
VVOS

Vivos Therapeutics

$4.53 /

-0.09 (-1.95%)

Vivos Therapeutics…

Vivos Therapeutics announced results from a national study commissioned by the Company to assess patients' airway function and OSA symptoms after undergoing the Vivos treatment. In the study, 28 percent of the 74 adult patients treated with the Company's FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, which is defined as patients having an Apnea Hypopnea Index score of less than five post-treatment. This real world patient data was gathered from multiple sites and has been submitted to the U.S. Food and Drug Administration to be used as part of the Company's process for obtaining 510k clearance for the DNA appliance to treat mild-to-moderate OSA. Patients who experienced little to no OSA symptoms may no longer require CPAP, neuro-stimulation, or other lifetime interventions. Other company case studies suggest potential long-term stability in the outcomes, although a clinical trial will be required to confirm whether or not these changes remain stable. Most importantly, these AHI findings were recorded with no oral appliance in place during sleep tests. Typically, when sleep tests are performed to evaluate the impact of OSA treatment, they are conducted with the treatment modality in place-whether it is CPAP, oral appliances, or neuro-stimulation implants. Since treatment with the DNA appliance is typically complete after just 12-24 months, patients' post-treatment sleep tests are performed and evaluated in the patient's natural state, unaided by any device. Eighty-two percent of the patients in the study showed some improvement in AHI scores, with 64 percent improving by at least one full category, such as moderate to mild OSA. In 15 percent of patients, AHI scores worsened, and in 4 percent of patients there was no change. Average treatment time with the Company's Class 1 DNA appliance for certain orofacial anomalies was just 14 months. Not all of the patients in the study had completed treatment at the time this data was collected and a small percentage of patients required additional cosmetic orthodontia.

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$4.53 /

-0.09 (-1.95%)

VVOS Vivos Therapeutics
$4.53 /

-0.09 (-1.95%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
  • 11
    Dec
VVOS Vivos Therapeutics
$4.53 /

-0.09 (-1.95%)

Hot Stocks
Vivos Therapeutics' dental tissue treatment shows 97% satisfaction in study » 08:08
07/07/21
07/07
08:08
07/07/21
08:08
VVOS

Vivos Therapeutics

$4.23 /

-0.27 (-6.00%)

Vivos Therapeutics has…

Vivos Therapeutics has unveiled new data from an independent patient survey related to its proprietary Vivos treatment for treating dental tissue anomalies and dentofacial malformations known to be associated with obstructive sleep apnea - OSA - and other debilitating health conditions. Key findings include: nearly all - 97 percent - of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. 29% of patients surveyed said that they searched for non-surgical alternatives to current standards of care for treating OSA. The Vivos treatment is typically completed in approximately 12 to 24 months, after which most patients no longer require ongoing intervention.

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$4.23 /

-0.27 (-6.00%)

VVOS Vivos Therapeutics
$4.23 /

-0.27 (-6.00%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
  • 11
    Dec
VVOS Vivos Therapeutics
$4.23 /

-0.27 (-6.00%)

Options
new option listings and one option delisting on June 30th » 08:30
06/30/21
06/30
08:30
06/30/21
08:30
ARKO

Arko Corp.

$9.05 /

-0.25 (-2.69%)

, AXLA

Axcella Health

$3.99 /

-0.04 (-0.99%)

, BAB

British Airways

$33.06 /

-0.005 (-0.02%)

, BMTX

BM Technologies

$12.69 /

+0.14 (+1.12%)

, BTRS

BTRS Holdings

$13.00 /

-0.7 (-5.11%)

, CLXT

Calyxt

$3.99 /

-0.08 (-1.97%)

, COGT

Cogent Biosciences

$8.03 /

+0.0598 (+0.75%)

, CTXR

Citius Pharmaceuticals

$3.51 /

-0.2 (-5.40%)

, DCRC

Decarbonization Plus Acquisition III

$10.46 /

-0.09 (-0.85%)

, ELYS

Elys Game Technology

$4.18 /

-0.17 (-3.91%)

, FBRX

Forte Biosciences

$32.67 /

-1.71 (-4.97%)

, FVE

Five Star Senior Living

$5.70 /

-0.19 (-3.23%)

, III

Information Services

$5.79 /

-0.05 (-0.86%)

, ISUN

iSun

$11.79 /

-0.63 (-5.07%)

, NEGG

Newegg Commerce

$10.94 /

+0.72 (+7.05%)

, NOVN

Novan

$10.20 /

-0.3 (-2.86%)

, NSPR

InspireMD

$5.09 /

-0.23 (-4.32%)

, OCUP

Ocuphire Pharma

$4.74 /

-0.11 (-2.27%)

, PANL

Pangaea Logistics

$4.96 /

+0.15 (+3.12%)

, RADI

Radius Global Infrastructure

$14.40 /

-0.21 (-1.44%)

, SQZ

SQZ Biotechnologies

$13.92 /

-0.3 (-2.11%)

, TBLA

Taboola

/

+

, TGLS

Tecnoglass

$20.60 /

-0.2325 (-1.12%)

, TLIS

Talis Biomedical

$10.65 /

-0.89 (-7.71%)

, VMD

Viemed Healthcare

$7.47 /

+ (+0.00%)

, VVOS

Vivos Therapeutics

$4.87 /

-0.12 (-2.40%)

, YQ

17 Education & Technology

$3.47 /

-0.17 (-4.67%)

, IACA

ION Acquisition Corp 1

$10.51 /

+0.33 (+3.24%)

New option listings for…

New option listings for June 30th include iShares Agency Bond (AGZ), ARKO Corporation (ARKO), Axcella Health Inc (AXLA), PowerShares Build America Bond Portfolio (BAB), BM Technologies Inc (BMTX), BTRS Holdings Inc (BTRS), Calyxt Inc (CLXT), Cogent Biosciences Inc (COGT), Citius Pharmaceuticals Inc (CTXR), Decarbonization Plus Acquisition Corporation III (Class A Stock) (DCRC), Elys Game Technology Corporation (ELYS), Forte Biosciences (FBRX), Franklin FTSE Brazil ETF (FLBR), Five Star Quality (FVE), IQ S&P High Yield Low Volatility Bond ETF (HYLV), Information Services (III), iSun Inc (ISUN), KraneShares MSCI China Clean Technology Index ETF (KGRN), Newegg Commerce Inc (NEGG), Novan (NOVN), InspireMD (NSPR), Ocuphire Pharma Inc (OCUP), Pangaea Logistics (PANL), WisdomTree CBOE S&P 500 PutWrite Strategy Fund (PUTW), Radius Global Infrastructure Inc (Class A Stock) (RADI), Schwab 1 to 5 Year Corporate Bond ETF (SCHJ), SQZ Biotechnologies Company (SQZ), Taboola com Ltd (TBLA), Tecnoglass (TGLS), SPDR Barclays 1 to 10 Year TIPS (TIPX), Talis Biomedical Corporation (TLIS), VieMed Healthcare Inc (VMD), Vivos Therapeutics Inc (VVOS), Invesco S&P SmallCap Value with Momentum ETF (XSVM), 17 Education and Technology Group Inc (ADS) (YQ), and YieldShares High Income (YYY). Option delistings effective June 30th include ION Acquisition Corp 1 Ltd (Class A Stock) (IACA).

ShowHide Related Items >><<
VVOS Vivos Therapeutics
$4.87 /

-0.12 (-2.40%)

VMD Viemed Healthcare
$7.47 /

+ (+0.00%)

TLIS Talis Biomedical
$10.65 /

-0.89 (-7.71%)

TGLS Tecnoglass
$20.60 /

-0.2325 (-1.12%)

TBLA Taboola
/

+

SQZ SQZ Biotechnologies
$13.92 /

-0.3 (-2.11%)

RADI Radius Global Infrastructure
$14.40 /

-0.21 (-1.44%)

PANL Pangaea Logistics
$4.96 /

+0.15 (+3.12%)

OCUP Ocuphire Pharma
$4.74 /

-0.11 (-2.27%)

NSPR InspireMD
$5.09 /

-0.23 (-4.32%)

NOVN Novan
$10.20 /

-0.3 (-2.86%)

NEGG Newegg Commerce
$10.94 /

+0.72 (+7.05%)

ISUN iSun
$11.79 /

-0.63 (-5.07%)

III Information Services
$5.79 /

-0.05 (-0.86%)

IACA ION Acquisition Corp 1
$10.51 /

+0.33 (+3.24%)

FVE Five Star Senior Living
$5.70 /

-0.19 (-3.23%)

FBRX Forte Biosciences
$32.67 /

-1.71 (-4.97%)

ELYS Elys Game Technology
$4.18 /

-0.17 (-3.91%)

DCRC Decarbonization Plus Acquisition III
$10.46 /

-0.09 (-0.85%)

CTXR Citius Pharmaceuticals
$3.51 /

-0.2 (-5.40%)

COGT Cogent Biosciences
$8.03 /

+0.0598 (+0.75%)

CLXT Calyxt
$3.99 /

-0.08 (-1.97%)

BTRS BTRS Holdings
$13.00 /

-0.7 (-5.11%)

AXLA Axcella Health
$3.99 /

-0.04 (-0.99%)

ARKO Arko Corp.
$9.05 /

-0.25 (-2.69%)

ARKO Arko Corp.
$9.05 /

-0.25 (-2.69%)

03/19/21 Stifel
Arko Corp. initiated with a Buy at Stifel
02/05/21
Fly Intel: Top five analyst initiations
02/05/21 Raymond James
Arko Corp. initiated with a Strong Buy at Raymond James
02/04/21 Raymond James
Arko Corp. initiated with a Strong Buy at Raymond James
AXLA Axcella Health
$3.99 /

-0.04 (-0.99%)

06/03/21 Chardan
Axcella Health price target raised to $16 from $10 at Chardan
04/13/21 Piper Sandler
Piper says IND clearance sets up Axcella Health for potential NASH 'home run'
03/22/21 Wedbush
Axcella Health price target lowered to $11 from $19 at Wedbush
03/18/21 Chardan
Axcella Health moving forward with two lead programs, says Chardan
BAB British Airways
$33.06 /

-0.005 (-0.02%)

BMTX BM Technologies
$12.69 /

+0.14 (+1.12%)

06/03/21 Maxim
BM Technologies initiated with a Buy at Maxim
BTRS BTRS Holdings
$13.00 /

-0.7 (-5.11%)

04/30/21 JPMorgan
Billtrust initiated with a Neutral at JPMorgan
04/22/21 Cowen
Billtrust initiated with an Outperform at Cowen
03/18/21 KeyBanc
Billtrust initiated with an Overweight at KeyBanc
03/10/21 Needham
Billtrust initiated with a Buy at Needham
CLXT Calyxt
$3.99 /

-0.08 (-1.97%)

05/10/21 Canaccord
Calyxt price target lowered to $7 from $16 at Canaccord
02/16/21 Canaccord
Calyxt price target raised to $16 from $8 at Canaccord
12/15/20 Berenberg
Calyxt initiated with a Buy at Berenberg
12/10/20
Fly Intel: Top five analyst initiations
COGT Cogent Biosciences
$8.03 /

+0.0598 (+0.75%)

06/09/21 Jefferies
Cogent Biosciences assumed with a Buy at Jefferies
05/12/21 Piper Sandler
Piper remain buyers of Cogent Biosciences after 'relatively quiet' Q1 report
12/23/20 Piper Sandler
Cogent Biosciences initiated with an Overweight at Piper Sandler
12/17/20 SVB Leerink
Cogent Biosciences initiated with an Outperform at SVB Leerink
CTXR Citius Pharmaceuticals
$3.51 /

-0.2 (-5.40%)

DCRC Decarbonization Plus Acquisition III
$10.46 /

-0.09 (-0.85%)

ELYS Elys Game Technology
$4.18 /

-0.17 (-3.91%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 H.C. Wainwright
Elys Game Technology initiated with a Buy at H.C. Wainwright
FBRX Forte Biosciences
$32.67 /

-1.71 (-4.97%)

05/14/21
Fly Intel: Top five analyst initiations
05/14/21 B. Riley
B. Riley starts Forte Biosciences with Buy rating, $73 price target
05/13/21 B. Riley
Forte Biosciences initiated with a Buy at B. Riley
03/26/21 Citi
Forte Biosciences initiated with a Buy at Citi
FVE Five Star Senior Living
$5.70 /

-0.19 (-3.23%)

05/10/21 B. Riley
Five Star Senior Living price target raised to $8 from $7.50 at B. Riley
04/12/21 B. Riley
Five Star Senior Living price target lowered to $7.50 from $8.50 at B. Riley
12/10/20 Wells Fargo
Diversified Healthcare Trust downgraded to Underweight from Equal Weight at Wells Fargo
08/25/20
Fly Intel: Top five analyst initiations
III Information Services
$5.79 /

-0.05 (-0.86%)

05/12/21 Barrington
Information Services upgraded to Outperform from Market Perform at Barrington
05/12/21 Noble Capital
Information Services price target raised to $7 from $5 at Noble Capital
ISUN iSun
$11.79 /

-0.63 (-5.07%)

06/02/21 Alliance Global Partners
iSun price target lowered to $21.40 from $24 at Alliance Global Partners
NEGG Newegg Commerce
$10.94 /

+0.72 (+7.05%)

NOVN Novan
$10.20 /

-0.3 (-2.86%)

06/17/21 Needham
Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham
06/14/21 H.C. Wainwright
Novan price target raised to $28 from $20 at H.C. Wainwright
06/11/21 Roth Capital
Novan price target raised to $40 from $26 at Roth Capital
04/22/21
Fly Intel: Top five analyst initiations
NSPR InspireMD
$5.09 /

-0.23 (-4.32%)

10/16/20 Alliance Global Partners
InspireMD initiated with a Buy at Alliance Global Partners
OCUP Ocuphire Pharma
$4.74 /

-0.11 (-2.27%)

06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
04/05/21 Alliance Global Partners
Ocuphire Pharma initiated with a Buy at Alliance Global Partners
03/29/21 JonesTrading
Ocuphire Pharma initiated with a Buy at JonesTrading
03/15/21 Canaccord
Ocuphire shares should move 'meaningfully higher' on data, says Canaccord
PANL Pangaea Logistics
$4.96 /

+0.15 (+3.12%)

RADI Radius Global Infrastructure
$14.40 /

-0.21 (-1.44%)

04/22/21 Raymond James
Raymond James starts Radius Global Infrastructure at Outperform on pricing power
04/22/21 Raymond James
Radius Global Infrastructure initiated with an Outperform at Raymond James
04/12/21 Jefferies
Radius Global Infrastructure initiated with a Buy at Jefferies
12/29/20 LightShed Partners
Radius Global Infrastructure initiated with a Buy at LightShed Partners
SQZ SQZ Biotechnologies
$13.92 /

-0.3 (-2.11%)

03/30/21 Brookline
SQZ Biotechnologies initiated with a Buy at Brookline
01/07/21 Evercore ISI
SQZ Biotechnologies initiated with an Outperform at Evercore ISI
11/24/20 Stifel
SQZ Biotechnologies initiated with a Buy at Stifel
11/24/20 BofA
SQZ Biotechnologies initiated with a Buy at BofA
TBLA Taboola
/

+

TGLS Tecnoglass
$20.60 /

-0.2325 (-1.12%)

06/02/21
Fly Intel: Top five analyst downgrades
06/02/21 B. Riley
Tecnoglass downgraded to Neutral after 240% rally at B. Riley
06/02/21 B. Riley
Tecnoglass downgraded to Neutral from Buy at B. Riley
05/10/21 B. Riley
Tecnoglass price target raised to $17 from $14 at B. Riley
TLIS Talis Biomedical
$10.65 /

-0.89 (-7.71%)

05/12/21 Piper Sandler
Talis Biomedical price target lowered to $13 from $17 at Piper Sandler
03/09/21 JPMorgan
Talis Biomedical initiated with an Overweight at JPMorgan
03/09/21 BofA
BofA starts Talis Biomedical at Neutral with $14 price target
03/09/21 BTIG
Talis Biomedical initiated with a Buy at BTIG
VMD Viemed Healthcare
$7.47 /

+ (+0.00%)

03/05/21 RBC Capital
Viemed Healthcare initiated with an Outperform at RBC Capital
VVOS Vivos Therapeutics
$4.87 /

-0.12 (-2.40%)

01/11/21 Craig-Hallum
Craig-Hallum bullish on Vivos Therapeutics, initiates with a Buy
01/11/21 Craig-Hallum
Vivos Therapeutics initiated with a Buy at Craig-Hallum
01/05/21 Roth Capital
Vivos Therapeutics initiated with a Buy at Roth Capital
YQ 17 Education & Technology
$3.47 /

-0.17 (-4.67%)

06/16/21 Morgan Stanley
Morgan Stanley cuts 17 Education & Technology to Underweight on K9-related risk
06/16/21 Morgan Stanley
TAL Education cut to Underweight on K9-related business risk at Morgan Stanley
06/16/21 Morgan Stanley
New Oriental Education downgraded on K9-related business risk at Morgan Stanley
06/16/21 Morgan Stanley
17 Education downgraded to Underweight from Overweight at Morgan Stanley
IACA ION Acquisition Corp 1
$10.51 /

+0.33 (+3.24%)

VMD Viemed Healthcare
$7.47 /

+ (+0.00%)

TGLS Tecnoglass
$20.60 /

-0.2325 (-1.12%)

SQZ SQZ Biotechnologies
$13.92 /

-0.3 (-2.11%)

RADI Radius Global Infrastructure
$14.40 /

-0.21 (-1.44%)

PANL Pangaea Logistics
$4.96 /

+0.15 (+3.12%)

OCUP Ocuphire Pharma
$4.74 /

-0.11 (-2.27%)

III Information Services
$5.79 /

-0.05 (-0.86%)

FVE Five Star Senior Living
$5.70 /

-0.19 (-3.23%)

FBRX Forte Biosciences
$32.67 /

-1.71 (-4.97%)

ELYS Elys Game Technology
$4.18 /

-0.17 (-3.91%)

CTXR Citius Pharmaceuticals
$3.51 /

-0.2 (-5.40%)

COGT Cogent Biosciences
$8.03 /

+0.0598 (+0.75%)

BTRS BTRS Holdings
$13.00 /

-0.7 (-5.11%)

AXLA Axcella Health
$3.99 /

-0.04 (-0.99%)

ARKO Arko Corp.
$9.05 /

-0.25 (-2.69%)

  • 01
    Jul
  • 17
    Jun
  • 12
    Feb
  • 12
    Feb
  • 04
    Feb
  • 11
    Dec
  • 02
    Dec
  • 04
    Dec
  • 29
    Oct
  • 30
    Oct
DCRC Decarbonization Plus Acquisition III
$10.46 /

-0.09 (-0.85%)

TLIS Talis Biomedical
$10.65 /

-0.89 (-7.71%)

NOVN Novan
$10.20 /

-0.3 (-2.86%)

IACA ION Acquisition Corp 1
$10.51 /

+0.33 (+3.24%)

DCRC Decarbonization Plus Acquisition III
$10.46 /

-0.09 (-0.85%)

BTRS BTRS Holdings
$13.00 /

-0.7 (-5.11%)

IACA ION Acquisition Corp 1
$10.51 /

+0.33 (+3.24%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.